 |
|
Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline
Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim,
Clin Mol Hepatol. 2021;27(4):515-523. Published online 2021 Sep 17 DOI: https://doi.org/10.3350/cmh.2021.0293
|
|
Citations to this article as recorded by
 Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”
Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen
Clinical and Molecular Hepatology.2023; 29(1): 176. CrossRef SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes
Luke Baldelli, Thomas Marjot, Eleanor Barnes, A. Sidney Barritt, Gwilym J. Webb, Andrew M. Moon
Gut and Liver.2023; 17(1): 12. CrossRef
Acute
Budd‐Chiari
syndrome with thrombotic thrombocytopenia after
BNT162b2 mRNA
vaccination
Pil S. Sung, Jung S. Oh, Joon‐Il Choi
Liver International.2022; 42(6): 1447. CrossRef Forms of cholangitis to be considered after SARS-CoV-2 infection
Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim
Clinical and Molecular Hepatology.2022; 28(4): 929. CrossRef Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study
Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung
Clinical and Molecular Hepatology.2022; 28(4): 926. CrossRef
|